$35 Insulin Cap Deal Reached by US Senators | Reuters Health Information

A bipartisan agreement reached by U.S. Senators aims to cap the monthly cost of insulin at $35, Semafor reported Wednesday. The deal, which builds on existing efforts to lower prescription drug costs, could significantly impact millions of Americans living with diabetes who rely on this life-saving medication. While a $35 cap is already in place for those on Medicare, this new legislation seeks to extend those savings to individuals with private and employer-based health insurance plans.

Expanding Access: The INSULIN Act of 2026

The legislation, formally known as the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026, is co-sponsored by Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME). Shaheen, who co-chairs the Senate Diabetes Caucus, emphasized the unacceptable reality that one in five Americans with diabetes are forced to ration their insulin due to rising costs. The bill combines a proposal to extend the $35 cap to those with private insurance with a separate initiative led by Senators Raphael Warnock (D-GA) and John Kennedy (R-LA). This companion proposal establishes a five-year pilot program to cap insulin costs at $35 per month for uninsured patients in ten targeted states.

This effort represents a consolidation of previous attempts. In 2024, both the Shaheen-Collins bill and the Warnock-Kennedy proposal failed to pass the Senate. This year, lawmakers opted to combine their efforts, partially driven by a reduction in the pilot program’s cost from $500 million to $100 million. The proposed cap for consumers would be $35/month or 25% of the list price for the insulin, whichever is lower.

The Landscape of Insulin Costs and Existing Caps

The need for such legislation stems from the consistently increasing price of insulin. For years, the cost of the medication has been a significant burden for many, leading to tough choices about healthcare spending and, in some cases, dangerous rationing. Currently, Medicare beneficiaries have access to insulin at a capped price of $35 per month, a provision enacted through the Inflation Reduction Act of 2022. This law also limits cost-sharing for insulin covered under Medicare Part B to $35 per month and eliminates deductibles for insulin under both Part D and Part B.

Prior to the Inflation Reduction Act, the Trump Administration implemented a voluntary model, the Part D Senior Savings Model, which allowed participating Medicare Part D plans to offer insulin at no more than $35 per month. However, this model was time-limited (2021-2023) and participation was relatively low, with less than half of all Part D plans choosing to participate each year.

What Does This Signify for People with Diabetes?

Diabetes is a chronic metabolic disorder characterized by elevated blood sugar levels. Insulin, a hormone produced by the pancreas, is crucial for regulating blood glucose. People with type 1 diabetes do not produce insulin and require lifelong insulin therapy. Many with type 2 diabetes also require insulin to manage their condition. Without sufficient insulin, individuals with diabetes can experience serious health complications, including diabetic ketoacidosis, nerve damage, kidney disease, and vision loss.

Extending the $35 insulin cap to those with private insurance could provide substantial financial relief to millions. The exact number of people who would benefit is difficult to pinpoint, as it depends on factors like insurance plan formularies, individual insulin needs, and the prevalence of diabetes across different insurance groups. However, the American Diabetes Association estimates that over 7.5 million Americans use insulin.

Pilot Program for the Uninsured: A Targeted Approach

The inclusion of a pilot program for uninsured patients is a critical component of the legislation. Uninsured individuals often face the highest out-of-pocket costs for medications, making insulin particularly inaccessible. The five-year pilot program, targeting ten states, aims to assess the feasibility and impact of a broader $35 insulin cap for this vulnerable population. The reduced cost of the pilot – down from $500 million to $100 million – reflects a compromise reached by lawmakers to secure broader support for the bill.

Looking Ahead: Procedural Steps and Potential Challenges

The passage of this bipartisan agreement is a significant step, but several hurdles remain. The bill must now pass through the full Senate and then the House of Representatives before being signed into law by the President. The timeline for this process is uncertain, but lawmakers have expressed a commitment to moving the legislation forward expeditiously.

Potential challenges include securing sufficient votes in both chambers of Congress and addressing concerns from pharmaceutical companies and insurance providers. Some argue that capping insulin prices could stifle innovation and reduce access to newer insulin formulations. However, proponents of the bill maintain that ensuring affordable access to life-saving medication is a moral imperative and that alternative solutions can be explored to support pharmaceutical innovation.

Further legislative action and ongoing monitoring of insulin prices and access will be essential to ensure that this agreement translates into meaningful relief for individuals with diabetes. The Department of Health and Human Services will likely play a key role in implementing the pilot program and tracking its impact on uninsured patients. Continued dialogue between lawmakers, healthcare providers, and patient advocacy groups will be crucial to address any unforeseen challenges and refine the policy as needed.